All Type of News
Product restructuring daunting task
Influenced by the government’s plan to cut drug prices by an average of 14 percent starting next year, smaller pharmaceutical firms face at times a daunting task of selecting unprofitable products.
However, they ar...
Pharmaceutical firms’ liquidity conditions remain sound
Listed drug firms’ liquidity conditions remained firm in June as companies are set to issue more corporate bonds and increase borrowings as part of efforts to secure capital on worries the ongoing uncertainty will con...
Niels Hessmann to head Bayer Korea
Bayer Korea said Tuesday that it appointed Niels Hessmann as its new president.
Hessmann will replace outgoing Bayer Healthcare CEO Friedrich Gause who served from October 2008.
He served as president of Bayer B...
National Assembly set to screen 38 bills
The National Assembly’s Health and Welfare Committee is expected to examine a total of 38 bills on November 9, including a bill to seek an approval of autologous cell therapy (ACT) with a Phase I study data only, when...
KPMA vows to defy measures designed to slash drug prices
Asserting that the government’s “ill-conceived” plan to cut drug prices would shake the pharmaceutical industry to its roots, member of the Korea Pharmaceutical Manufacturers Association pledged joint efforts to block...
Incentive drugs for low-priced dispensing top 4,631
The Health Insurance Review and Assessment Service (HIRA) said Tuesday that from 5,888 drugs whose bioequivalence was already endorsed, there are a total of 4,631 incentive drugs as of October, showing an increase of ...
Product restructuring to sweep pharmaceutical firms
Influenced by the government’s plan to slash the price of about half the drugs on the market by an average of 14 percent, a growing number of pharmaceutical firms are scrambled to go through product restructuring star...
Gilead Science Korea names new executives in shake-up
In an effort to bolster its localization efforts, Gilead Science Korea said Thursday that it has appointed two new executive directors – Chung Yeon-sim, head of the Regulatory and Market Access Team and Ban Joon-woo, ...
Assembly-private panel discussion gains no fruit
Lawmakers of the National Assembly’s Health and Welfare Committee and four law and patent experts held a public hearing on Monday over the impacts that its free trade deals with the U.S. would cause in domestic pharma...
New consultative body to discuss drug pricing system eyed
The Ministry of Health and Welfare said Monday it will newly set up a consultative body with representatives from the government, industry and medical circles to revise the current drug-pricing plan takes effect last ...
